## **AMENDMENTS TO THE CLAIMS**

Applicant has submitted a new complete claim set showing marked-up claims with insertions indicated by underlining and deletions indicated by strikethroughs or double-bracketing. This listing of claims will replace all prior versions, and listings of claims in the application.

## LISTING OF CLAIMS

15. (Currently Amended) A compound of the formula (II):

$$\begin{array}{c|c}
NH_2 \\
N \\
N \\
R_3
\end{array}$$

$$\begin{array}{c|c}
N \\
R_1 \\
R_1
\end{array}$$

п

wherein:

R<sub>3</sub> is selected from the group consisting of:

-Z-Ar,

-Z-Ar'-Y-R4,

 $-Z-Ar'-X-Y-R_4$ 

-Z-, Ar'-R<sub>5</sub>, and

-Z-Ar'-X-R<sub>5</sub>;

Z is selected from the group consisting of a bond, alkylene, alkenylene, and alkynylene wherein alkylene, alkenylene, and alkynylene are optionally interrupted with -O-;

Ar is selected from the group consisting of aryl and heteroaryl both of which can be unsubstituted or can be substituted by one or more substituents independently selected from the group consisting of alkyl, alkenyl, alkoxy, methylenedioxy, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, hydroxyalkyl, mercapto, cyano, carboxy, formyl, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, heterocyclylalkylenyl, amino, alkylamino, and dialkylamino;

Ar'is selected from the group consisting of arylene and heteroarylene both of which can be unsubstituted or can be substituted by one or more substituents independently selected from the group consisting of alkyl, alkenyl, alkoxy, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, hydroxyalkyl, mercapto, cyano, carboxy, formyl, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, heterocyclylalkylenyl, amino, alkylamino, and dialkylamino;

R is selected from the group consisting of alkyl, alkoxy, hydroxy, halogen, and trifluoromethyl;

n is 0 or 1;

R<sub>I</sub> is selected from the group consisting of:

 $-R_4$ 

 $-X-R_4$ 

-X-Y-R4,

-X-Y-X-Y-R<sub>4</sub>, and

-X-R5

R<sub>2</sub> is selected from the group consisting of:

-R<sub>4</sub>,

-X-R₄.

-X-Y-R<sub>4</sub>, and

 $-X-R_5$ ;

each X is independently selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, heteroarylene, and heterocyclylene wherein the alkylene, alkenylene, and alkynylene groups can be optionally interrupted by arylene, heteroarylene or heterocyclylene or by one or more-O-groups;

each Y is independently selected from the group consisting of:

 $-S(O)_{0-2}$ -,

 $-S(O)_2-N(R_8)-,$ 

 $-C(R_6)-$ 

-C(R<sub>6</sub>)-O-,

 $-O-C(R_6)-,$  -O-C(O)-O-,  $-N(R_8)-Q-,$   $-C(R_6)-N(R_8)-,$   $-O-C(R_6)-N(OR_9)-,$   $-(R_6)-N(OR_9)-,$   $-N-C(R_6)-N-W R_7$   $-N-R_7-N-Q R_7$  -V-N  $R_{10}$ , and  $-V-C(R_9)-N$   $R_{10}$ 

each R<sub>4</sub> is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroarylalkylenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, amino, alkylamino, dialkylamino, (dialkylamino) alkyleneoxy, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo;

each R<sub>5</sub> is independently selected from the group consisting of:

$$-N-C(R_6)$$
  $-N-S(O)_2$   $-V-N$   $(CH_2)_a$   $A$   $(CH_2)_b$   $A$   $(CH_2)_b$   $A$   $(CH_2)_b$   $A$   $(CH_2)_b$   $A$ 

each  $R_6$  is independently selected from the group consisting of =O and =S; each  $R_7$  is independently  $C_{2-7}$  alkylene;

each R<sub>8</sub> is independently selected from the group consisting of hydrogen, alkyl, alkoxyalkylenyl, and arylalkylenyl;

each  $R_9$  is independently selected from the group consisting of hydrogen and alkyl; each  $R_{10}$  is independently  $C_{3-8}$  alkylene;

each A is independently selected from the group consisting of -O-,-C (O)-, -S(O) $_{0-2}$ -, -CH $_{2}$ -, and-N(R<sub>4</sub>)-;

each Q is independently selected from the group consisting of a bond,  $-C(R_6)$ -,  $-C(R_6)$ -C(R<sub>6</sub>)-,  $-S(O)_2$ -,  $-C(R_6)$ -N(R<sub>8</sub>)-W-,  $-S(O)_2$ -N(R<sub>8</sub>)-,  $-C(R_6)$ -O-, and  $-C(R_6)$ -N(OR<sub>9</sub>)-;

each V is independently selected from the group consisting of  $-C(R_6)$ -,  $-O-C(R_6)$ -,  $-N(R_8)$ -C  $(R_6)$ -, and  $-S(O)_2$ -;

each W is independently selected from the group consisting of a bond, -C(O)-, and -S(O)<sub>2</sub>-; and

a and b are independently integers from 1 to 6 with the proviso that a + b is  $\leq 7$ ; or a pharmaceutically acceptable salt thereof.

- 16. (Previously Presented) The compound or salt of claim 15 wherein n is 0.
- 17. (Previously Presented) The compound or salt of claim 15 wherein R<sub>3</sub> is selected from the group consisting of -Z-Ar, -Z-Ar'-X-Y-R<sub>4</sub>, and -Z-Ar'-Y-R<sub>4</sub>.
- 18. (Previously Presented) The compound or salt of claim 17 wherein X is  $C_{1-2}$  alkylene; Y is -NH-S(O)<sub>2</sub>-, -S(O)<sub>2</sub>-, -C(O)-, or -C(O)O-; and R<sub>4</sub> is  $C_{1-4}$ alkyl or phenyl.

- 19. (Previously Presented) The compound or salt of claim 18 wherein Z is a bond, alkylene, or alkylene interrupted by -O-.
- 20. (Previously Presented) The compound or salt of claim 19 wherein Z is C<sub>1-3</sub> alkylene.
- 21. (Previously Presented) The compound or salt of claim 19 wherein Z is a bond.
- 22. (Previously Presented) The compound or salt of claim 15 wherein R<sub>1</sub> is selected from the group consisting of alkyl, arylalkylenyl, aryloxyalkylenyl, hydroxyalkyl, dihydroxyalkyl, alkylsulfonylalkylenyl, heterocyclylalkylenyl wherein heterocyclyl is optionally substituted by one or more alkyl groups, -X-Y-R<sub>4</sub>, and-X-R<sub>5</sub>; wherein X is alkylene, Y is -N(R<sub>8</sub>)-C(O)-, -N(R<sub>8</sub>)-S(O)<sub>2</sub>-,

-N( $R_8$ )-C( $R_6$ )-N ( $R_8$ )-, or ;  $R_4$  is alkyl, aryl, arylalkylenyl, or heteroaryl, each of which is optionally substituted by one or more substituents selected from the group consisting of alkyl, alkoxy, halogen, or dialkylamino; and  $R_5$  is

$$-N-C(R_6)$$
  $-N-S(O)_2$   $-N(R_8)-C(O)-N$  A  $(CH_2)_b$ 

- 23. (Previously Presented) The compound or salt of claim 22 wherein R<sub>I</sub> is selected from the group consisting of 2-hydroxy-2-methylpropyl, 2-methylpropyl, propyl, 2,3-dihydroxypropyl, 4-[(methylsulfonyl) amino]butyl, 2-methyl-2-[(methylsulfonyl)amino]propyl, 2-[(cyclohexylcarbonyl)amino]-2-methylpropyl, 4-(1,1-dioxidoisothiazolidin-2-yl)butyl, tetrahydro-2*H*-pyran-4-yhnethyl, and (2,2-dimethyl-1,3-dioxolan-4-yl)methyl.
- 24. (Previously Presented) The compound or salt of claim 15 wherein  $R_2$  is selected from the group consisting of hydrogen, alkyl, alkoxyalkylenyl, and -X-N( $R_8$ )-C( $R_6$ )-N( $R_8$ )-R<sub>4</sub> wherein X is  $C_{1-4}$ alkylene, and  $R_4$  is  $C_{1-4}$ alkyl.

Docket No.: C1271.70021US02

Application No. 10/595,103 Amendment dated March 16, 2009 Reply to Office Action dated September 15, 2008

- 25. (Previously Presented) The compound or salt of claim 24 wherein R<sub>2</sub> is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, ethoxymethyl, methoxymethyl, 2-methoxyethyl, and methylaminocarbonylaminomethyl.
- 26. (Previously Presented) The compound or salt of claim 25 wherein R<sub>2</sub> is selected from the group consisting of ethyl, propyl, 2-methoxyethyl, ethoxymethyl, and methoxymethyl.
- 27. (Currently Amended) A compound of the formula III:

$$R_{3-1}$$
 $NH_2$ 
 $NH_2$ 
 $N$ 
 $R_1$ 
 $R_1$ 

Ш

wherein:

R<sub>3-1</sub> is-Z-Ar;

Z is selected from the group consisting of a bond, alkylene, alkenylene, and alkynylene wherein alkylene, alkenylene, and alkynylene are optionally interrupted with -O-;

Ar is selected from the group consisting of aryl and heteroaryl both of which can be unsubstituted or can be substituted by one or more substituents independently selected from the group consisting of alkyl, alkenyl, alkoxy, methylenedioxy, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, hydroxyalkyl, mercapto, cyano, carboxy, formyl, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, heterocyclylalkylenyl, amino, alkylamino, and dialkylamino;

R is selected from the group consisting of alkyl, alkoxy, hydroxy, halogen, and trifluoromethyl;

n is 0 or 1;

R<sub>l</sub> is selected from the group consisting of:

 $-R_4$ 

 $-X-R_4$ ,

 $-X-Y-R_4$ 

-X-Y-X-Y-R<sub>4</sub>, and

-X-R<sub>5</sub>;

R<sub>2</sub> is selected from the group consisting of:

 $-R_4$ 

 $-X-R_4$ 

-X-Y-R<sub>4</sub>, and

-X-R<sub>5</sub>;

each X is independently selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, heteroarylene, and heterocyclylene wherein the alkylene, alkenylene, and alkynylene groups can be optionally interrupted by arylene, heteroarylene or heterocyclylene or by one or more -O- groups;

8

each Y is independently selected from the group consisting of:

 $-S(O)_{0-2}$ -,

 $-S(O)_2-N(R_8)-,$ 

 $-C(R_6)-,$ 

 $-C(R_6)-O-,$ 

 $-O-C(R_6)-$ 

-O-C(O)-O-,

 $-N(R_8)-Q-,$ 

 $-C(R_6)-N(R_8)-,$ 

 $-O-C(R_6)-N(R_8)-$ ,

 $-C(R_6)-N(OR_9)-,$ 

$$N-Q R_{10}$$
 $N-Q R_{10}$ 
 $N-Q R_{7}$ 
 $N-Q R_{7}$ 
 $N-Q R_{7}$ 
 $N-Q R_{7}$ 
 $R_{10}$ 
 $R_{10}$ 
 $R_{10}$ 
 $R_{10}$ 

each R<sub>4</sub> is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroarylalkylenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroarylalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, amino, alkylamino, dialkylamino, (dialkylamino) alkyleneoxy, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo;

each R<sub>5</sub> is independently selected from the group consisting of:

$$-N-C(R_6)$$
  $-N-S(O)_2$   $-V-N$   $A$   $(CH_2)_b$   $A$   $(CH_2)_b$   $A$   $(CH_2)_b$   $A$   $(CH_2)_b$   $A$ 

each  $R_6$  is independently selected from the group consisting of =O and =S; each  $R_7$  is independently  $C_{2-7}$ alkylene;

each  $R_8$  is independently selected from the group consisting of hydrogen, alkyl, alkoxyalkylenyl, and arylalkylenyl;

each  $R_9$  is independently selected from the group consisting of hydrogen and alkyl;

10

each R<sub>10</sub> is independently C<sub>3-8</sub> alkylene;

each A is independently selected from the group consisting of -O-, -C(O)-, -S(O)<sub>0-2</sub>-, -CH<sub>2</sub>-, and -N(R<sub>4</sub>)-;

each Q is independently selected from the group consisting of a bond, -C(R<sub>6</sub>)-, -C(R<sub>6</sub>)-

 $C(R_6)$ -,  $-S(O)_2$ -,  $-C(R_6)$ - $N(R_8)$ -W-,  $-S(O)_2$ - $N(R_8)$ -,  $-C(R_6)$ -O-, and  $-C(R_6)$ - $N(OR_9)$ -;

each V is independently selected from the group consisting of  $-C(R_6)$ -,  $-O-C(R_6)$ -,  $-N(R_8)$ - $C(R_6)$ -, and  $-S(O)_2$ -;

each W is independently selected from the group consisting of a bond, -C(O)-, and -(O)<sub>2</sub>-; and

a and b are independently integers from 1 to 6 with the proviso that a + b is  $\leq 7$ ; or a pharmaceutically acceptable salt thereof.

- 28. (Previously Presented) The compound or salt of claim 27 wherein n is 0.
- 29. (Previously Presented) The compound or salt of claim 27 wherein Ar is phenyl or heteroaryl which is unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, nitro, cyano, carboxy, halogen, hydroxyalkyl, amino, alkylamino, dialkylamino, trifluoromethyl, trifluoromethoxy, and thienyl.
- 30. (Previously Presented) The compound or salt of claim 29 wherein heteroaryl is selected from the group consisting of benzothiazolyl, furanyl, imidazolyl, indolyl, isoxazolyl, oxadiazolyl, pyrazinyl, pyridinyl, pyrrolyl, thiazolyl, and thienyl.
- 31. (Previously Presented) The compound or salt of claim 27 wherein Z is a bond, alkylene, or alkylene interrupted by -O-.
- 32. (Previously Presented) The compound or salt of claim 31 wherein Z is C<sub>1-3</sub> alkylene.

33.

- (Previously Presented) The compound or salt of claim 31 wherein Z is a bond.
- 34. (Previously Presented) The compound or salt of claim 27 wherein R<sub>1</sub> is selected from the group consisting of alkyl, arylalkylenyl, aryloxyalkylenyl, hydroxyalkyl, dihydroxyalkyl, alkylsulfonylalkylenyl, heterocyclylalkylenyl wherein heterocyclyl is optionally substituted by one or more alkyl groups, -X-Y-R<sub>4</sub>, and-X-R<sub>5</sub>; wherein X is alkylene, Y is -N (R<sub>8</sub>)-C(O)-, -N(R<sub>8</sub>)-S(O)<sub>2</sub>-,

11

-N( $R_8$ )-C( $R_6$ )-N( $R_8$ )-, or  $R_{10}$ ;  $R_4$  is alkyl, aryl, arylalkylenyl, or heteroaryl, each of which is optionally substituted by one or more substituents selected from the group consisting of alkyl, alkoxy, halogen, or dialkylamino; and  $R_5$  is

$$-N-C(R_8)$$
  $-N-S(O)_2$   $-N(R_8)-C(O)-N$  A  $(CH_2)_b$ 

- 35. (Previously Presented) The compound or salt of claim 34 wherein R<sub>1</sub> is selected from the group consisting of 2-hydroxy-2-methylpropyl, 2-methylpropyl, propyl, 2,3-dihydroxypropyl, 4-[(methylsulfonyl) amino]butyl, 2-methyl-2-[(methylsulfonyl)amino]propyl, 2-[(cyclohexylcarbonyl)amino]-2-methylpropyl, 4-(1,1-dioxidoisothiazolidin-2-yl)butyl, tetrahydro-2*H*-pyran-4-ylmethyl, and (2, 2-dimethyl-1,3-dioxolan-4-yl)methyl.
- 36. (Previously Presented) The compound or salt of claim 27 wherein  $R_2$  is selected from the group consisting of hydrogen, alkyl, alkoxyalkylenyl, and -X-N( $R_8$ )-C( $R_6$ )-N( $R_8$ )-R<sub>4</sub> wherein X is  $C_{1-4}$  alkylene, and  $R_4$  is  $C_{1-4}$  alkyl.
- 37. (Previously Presented) The compound or salt of claim 36 wherein R<sub>2</sub> is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, ethoxymethyl, methoxymethyl, 2-methoxyethyl, and methylaminocarbonylaminomethyl.

38. (Previously Presented) The compound or salt of claim 37 wherein R<sub>2</sub> is selected from the group consisting of ethyl, propyl, 2-methoxyethyl, ethoxymethyl, and methoxymethyl.

12

39. (Currently Amended) A compound of the formula (VII):

$$(R)_{n} + R_{2}$$

$$R_{1-1}$$

$$VII$$

wherein:

R is selected from the group consisting of alkyl, alkoxy, hydroxy, halogen, and trifluoromethyl;

n is 0 or 1;

 $R_{1-1}$  is selected from the group consisting of:

 $-R_{4-1}$ ,

-X'-R<sub>4-1</sub>,

 $-X'-Y'-R_4$ 

 $-X'-Y'-X-Y-R_4$ , and

 $-X'-R_5;$ 

R<sub>2</sub> is selected from the group consisting of:

 $-R_4$ 

-X-R<sub>4</sub>,

 $-X-Y-R_4$ , and

-X-R<sub>5</sub>;

each X is independently selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, heteroarylene, and heterocyclylene wherein the alkylene, alkenylene, and alkynylene groups can be optionally interrupted by arylene, heteroarylene or heterocyclylene or by one or more -O-groups;

Docket No.: C1271.70021US02

X' is selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, heteroarylene, and heterocyclylene wherein the alkylene, alkenylene, and alkynylene groups can be optionally interrupted by an arylene, heteroarylene or heterocyclylene group;

each Y is independently selected from the group consisting of:

$$-S(O)_{0-2}$$
-,

$$-S(O)_2-N(R_8)-,$$

$$-C(R_6)-,$$

$$-C(R_6)-O-,$$

$$-O-C(R_6)-$$
,

$$-N(R_8)-Q-,$$

$$-C(R_6)-N(R_8)-,$$

$$-O-C(R_6)-N(R_8)-$$
,

$$-C(R_6)-N(OR_9)-,$$

$$-N-R_7-N-Q-$$

$$-V-N$$
  $R_{10}$  and

Y'is selected from the group consisting of:

$$-S(O)_2-N(R_8)-,$$

$$-C(R_6)-,$$

each R<sub>4</sub> is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroarylalkylenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroarylalkylenyl, heteroarylalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, amino, alkylamino, dialkylamino, (dialkylamino) alkyleneoxy, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo;

R<sub>4-1</sub> is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, alkylarylenyl, heteroarylalkylenyl, alkylarylenyl, and heterocyclyl

wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, aryl, heteroaryl, heterocyclyl, amino, alkylamino, dialkylamino, (dialkylamino) alkyleneoxy, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo;

each R<sub>5</sub> is independently selected from the group consisting of:

$$-N-C(R_6)$$
  $-N-S(O)_2$   $-V-N$   $(CH_2)_a$   $A$   $R_7$  , and  $R_{10}$   $N-C(R_8)-N$   $(CH_2)_b$   $A$   $(CH_2)_b$   $A$ 

each  $R_6$  is independently selected from the group consisting of =O and =S; each  $R_7$  is independently  $C_{2-7}$  alkylene;

each R<sub>8</sub> is independently selected from the group consisting of hydrogen, alkyl, alkoxyalkylenyl, and arylalkylenyl;

each  $R_9$  is independently selected from the group consisting of hydrogen and alkyl; each  $R_{10}$  is independently  $C_{3-8}$  alkylene;

each A is independently selected from the group consisting of-O-, -C(O)-, -S(O) $_{0-2}$ -, -CH $_2$ -, and -N(R $_4$ )-;

each Q is independently selected from the group consisting of a bond,

- $-C(R_6)-$ ,
- $-C(R_6)-C(R_6)-$ ,
- $-S(O)_{2}$ -,
- $-C(R_6)-N(R_8)-W-$
- $-S(O)_2-N(R_8)-$
- $-C(R_6)-O-$ , and
- $-(R_6)-N(OR_9)-;$

each V is independently selected from the group consisting of

- $-C(R_6)-$ ,
- -O-C(R<sub>6</sub>)-,

Reply to Office Action dated September 15,2008

$$-N(R_8)-C(R_6)-$$
, and  $-S(O)_2-$ ;

each W is independently selected from the group consisting of a bond, -C(O)-, and -S(O)<sub>2</sub>-; and

16

a and b are independently integers from 1 to 6 with the proviso that a+b is  $\leq 7$ ; or a pharmaceutically acceptable salt thereof; with the proviso that when  $R_{1-1}$  is hydrogen or 2-methylpropyl,  $R_2$  is other than hydrogen, and with the further proviso that when  $R_{1-1}$  is 2-methylpropenyl or 2-hydroxy-2-methylpropyl,  $R_2$  is other than methyl, ethoxymethyl, and hydroxymethyl.

40. (Previously Presented) The compound or salt of claim 39 wherein  $R_{1-1}$  is selected from the group consisting of alkyl, arylalkylenyl, hydroxyalkyl, dihydroxyalkyl, heterocyclylalkylenyl wherein heterocyclyl is optionally substituted by one or more alkyl groups,  $-X'-Y'-R_4$ , and  $-X'-R_5$ ; wherein X' is alkylene; Y' is -N ( $R_8$ )-Q-, and Q is selected from the group consisting of -C( $R_6$ )-,-  $S(O)_2$ -, and-C( $R_6$ )-N( $R_8$ )-W-;  $R_4$  is alkyl, aryl, arylalkylenyl, or heteroaryl, each of which is optionally substituted by one or more substituents selected from the group consisting of alkyl, alkoxy, halogen, or dialkylamino; and  $R_5$  is

$$-N-S(O)_2$$
  $-N(R_8)-C(O)-N$  A  $(CH_2)_b$ 

- 41. (Previously Presented) The compound or salt of claim 40 wherein R<sub>1-1</sub> is selected from the group consisting of 2-hydroxy-2-methylpropyl, 2-methylpropyl, propyl, 2,3-dihydroxypropyl, 4-[(methylsulfonyl)amino]butyl, 2-methyl-2-[(methylsulfonyl)amino]propyl, 2-[(cyclohexylcarbonyl)amino]-2-methylpropyl, 4-(1, 1-dioxidoisothiazolidin-2-yl)butyl, tetrahydro-2*H*-pyran-4-ylmethyl, and (2,2-dimethyl-1, 3-dioxolan-4-yl)methyl.
- 42. (Previously Presented) The compound or salt of claim 39 wherein n is 0.

Reply to Office Action dated September 15, 2008

43. (Previously Presented) The compound or salt of claim 39 wherein  $R_2$  is selected from the group consisting of hydrogen, alkyl, alkoxyalkylenyl, and -X-N( $R_8$ )-C( $R_6$ )-N( $R_8$ )-R<sub>4</sub> wherein X is  $C_{1-4}$  alkylene, and  $R_4$  is  $C_{1-4}$  alkyl.

17

- 44. (Previously Presented) The compound or salt of claim 43 wherein R<sub>2</sub> is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, ethoxymethyl, methoxymethyl, 2-methoxyethyl, and methylaminocarbonylaminomethyl.
- 45. (Previously Presented) The compound or salt of claim 44 wherein R<sub>2</sub> is selected from the group consisting of ethyl, propyl, ethoxymethyl, 2-methoxyethyl, and methoxymethyl.
- 46. (Previously Presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 15 in combination with a pharmaceutically acceptable carrier.
- 47. (Previously Presented) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of claim 15 to the animal.
- 48. (Previously Presented) A method of treating a viral disease in an animal in need thereof comprising administering a therapeutically effective amount of a compound or salt of claim 15 to the animal.
- 49. (Previously Presented) A method of treating a neoplastic disease in an animal in need thereof comprising administering a therapeutically effective amount of a compound or salt of claim 15 to the animal.
- 50. (Currently Amended) A compound of the formula (IX):

18

Docket No.: C1271.70021US02

wherein:

R is selected from the group consisting of alkyl, alkoxy, hydroxy, halogen, and trifluoromethyl;

n is 0 or 1;

 $R_{1-1}$  is selected from the group consisting of:

 $-R_{4-1}$ 

 $-X'-R_{4-1}$ 

-X'-Y'-R<sub>4</sub>

-X'-Y'-X-Y-R<sub>4</sub>, and

-X'-R<sub>5</sub> X'-R<sub>5</sub>;

R<sub>2</sub> is selected from the group consisting of:

 $-R_4$ 

 $-X-Y-R_4$ , and

 $-X-R_5$ ;

each X is independently selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, heteroarylene, and heterocyclylene wherein the alkylene, alkenylene, and alkynylene groups can be optionally interrupted by arylene, heteroarylene or heterocyclylene or by one or more -O- groups;

X' is selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, heteroarylene, and heterocyclylene wherein the alkylene, alkenylene, and alkynylene groups can be optionally interrupted by an arylene, heteroarylene or heterocyclylene group;

each Y is independently selected from the group consisting of:

 $-S(O)_{0-2}$ -, -S(O)2- $N(R_8)$ -,

 $-C(R_6)-.$ 

 $-C(R_6)-O_{-}$ 

19

 $-O-C(R_6)-$ ,

-O-C(O)-O-,

 $-N(R_8)-Q-,$ 

 $-C(R_6)-N(R_8)-,$ 

 $-O-C(R_6)-N(R_8)-,$ 

-C (R6)-N(OR9)-,

$$-N-R_7-N-Q-$$

$$-V-N$$
 , and

$$N-C(R_0)-N$$

Y 'is selected from the group consisting of:

-S(O)2-N(R8)-,

-C(R6)-,

-C(R6)-O-,

-N (R8)-Q-,

-C (R6)-N(R8)-,

-O-C (R6)-N(R8)-,

-C (R6)-N(OR9)-,

each R4 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroarylalkylenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroarylalkylenyl, heteroarylalkylenyl, heteroarylalkylenyl, heteroarylalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, amino, alkylamino, dialkylamino, (dialkylamino) alkyleneoxy, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo;

20

R<sub>4-1</sub> is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, alkylarylenyl, heteroarylalkylenyl, alkylheteroarylenyl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, aryl, heteroaryl, heterocyclyl, amino, alkylamino, dialkylamino, (dialkylamino) alkyleneoxy, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo;

each R<sub>5</sub> is independently selected from the group consisting of:

$$-N-C(R_6)$$
  $-N-S(O)_2$   $-V-N$   $A$   $R_7$  ,  $A$   $A$   $R_{10}$   $N-C(R_6)-N$   $A$   $C(CH_2)_a$   $A$ 

each  $R_6$  is independently selected from the group consisting of =O and =S; each  $R_7$  is independently  $C_{2-7}$  alkylene;

each R<sub>8</sub> is independently selected from the group consisting of hydrogen, alkyl, alkoxyalkylenyl, and arylalkylenyl;

each  $R_9$  is independently selected from the group consisting of hydrogen and alkyl; each  $R_{10}$  is independently  $C_{3-8}$  alkylene;

each A is independently selected from the group consisting of-O-,-C(O)-, -S(O)<sub>0-2</sub>-,-CH<sub>2</sub>-, and-N(R<sub>4</sub>)-;

each Q is independently selected from the group consisting of a bond,- $C(R_6)$ -, - $C(R_6)$ -C( $R_6$ )-, - $C(R_6)$ -N( $R_8$ )-W-, - $C(R_6)$ -N( $R_8$ )-, - $C(R_6)$ -O-, and - $C(R_6)$ -N( $R_8$ )-;

each V is independently selected from the group consisting of- $C(R_6)$ -, -  $(R_6)$ -, -N  $(R_8)$ -C  $(R_6)$ -, and- $S(O)_2$ -;

each W is independently selected from the group consisting of a bond,-C(O)-, and - $S(O)_{2-}$ ; and

a and b are independently integers from 1 to 6 with the proviso that a + b is  $\leq 7$ ; or a pharmaceutically acceptable salt thereof.

51. (Previously Presented) The compound or salt of claim 50 wherein  $R_{1-1}$  is selected from the group consisting of alkyl, arylalkylenyl, hydroxyalkyl, dihydroxyalkyl, heterocyclylalkylenyl wherein heterocyclyl is optionally substituted by one or more alkyl groups, -X'-Y'-R<sub>4</sub>, and -X'-R<sub>5</sub>; wherein X'is alkylene; Y'is-N ( $R_8$ )-Q-; and Q is selected from the group consisting of-C( $R_6$ )-,-S(O)<sub>2</sub>, and-C( $R_6$ )-N( $R_8$ )-W-;  $R_4$  is alkyl, aryl, arylalkylenyl, or heteroaryl, each of which is optionally substituted by one or more substituents selected from the group consisting of alkyl, alkoxy, halogen, or dialkylamino; and  $R_5$  is

Docket No.: C1271.70021US02

Application No. 10/595,103 Amendment dated March 16, 2009 Reply to Office Action dated September 15, 2008

$$-N-S(O)_2$$
  $-N(R_8)-C(O)-N$  A

## 52. (Currently Amended) A compound of the formula (XI):

XI

wherein:

R<sub>3</sub> is selected from the group consisting of:

-Z-Ar,

 $-Z-Ar'-X-Y-R_4$ 

- Z-Ar'-R<sub>5</sub>, and

 $-Z-Ar'-X-R_5$ ;

Z is selected from the group consisting of a bond, alkylene, alkenylene, and alkynylene wherein alkylene, alkenylene, and alkynylene are optionally interrupted with -O-;

Ar is selected from the group consisting of aryl and heteroaryl both of which can be unsubstituted or can be substituted by one or more substituents independently selected from the group consisting of alkyl, alkenyl, alkoxy, methylenedioxy, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, hydroxyalkyl, mercapto, cyano, carboxy, formyl, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, heterocyclylalkylenyl, amino, alkylamino, and dialkylamino;

Ar' is selected from the group consisting of arylene and heteroarylene both of which can be unsubstituted or can be substituted by one or more substituents independently selected from the group consisting of alkyl, alkenyl, alkoxy, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, hydroxyalkyl, mercapto, cyano, carboxy, formyl, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, heterocyclylalkylenyl, amino, alkylamino, and dialkylamino;

Application No. 10/595,103 Amendment dated March 16, 2009

Reply to Office Action dated September 15, 2008

R is selected from the group consisting of alkyl, alkoxy, hydroxy, halogen, and trifluoromethyl;

23

n is 0 or 1;

 $R_1$  is selected from the group consisting of:

- $-R_4$
- $-X-R_4$
- $-X-Y-R_4$
- -X-Y-X-Y-R<sub>4</sub>, and
- -X-R<sub>5</sub>;

R<sub>2</sub> is selected from the group consisting of:

- $-R_4$
- $-X-R_4$
- -X-Y-R<sub>4</sub>, and
- -X-R<sub>5</sub>;

each X is independently selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, heteroarylene, and heterocyclylene wherein the alkylene, alkenylene, and alkynylene groups can be optionally interrupted by arylene, heteroarylene or heterocyclylene or by one or more -O- groups;

each Y is independently selected from the group consisting of:

- $-S(O)_{0-2-}$
- $-S(O)_2-N(R_8)-,$
- $-C(R_6)-,$
- $-C(R_6)-O-$
- $-O-C(R_6)-$ ,
- -O-C(O)-O-,
- $-N(R_8)-Q-,$
- $-C(R_6)-N(R_8)-,$
- $-O-C(R_6)-N(R_8)-$
- $-C(R_6)-N(OR_9)-,$

$$N-Q R_{10}$$
,

 $N-Q R_{10}$ 
,

 $N-Q R_{7}$ 
,

 $N-C(R_{6})-N-W R_{7}$ 
,

 $N-C(R_{6})-N$ 
 $R_{10}$ 
, and

each R<sub>4</sub> is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroarylalkylenyl, alkynyl, aryl, arylalkylenyl, alkylarylenyl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroarylalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, amino, alkylamino, dialkylamino, (dialkylamino) alkyleneoxy, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo;

each R<sub>5</sub> is independently selected from the group consisting of:

$$-N - C(R_{e}) - N - S(O)_{2} - V - N - (CH_{2})_{a} A - (CH_{2})_{b} A$$

$$(CH_{2})_{b} A - (CH_{2})_{b} A$$

each  $R_6$  is independently selected from the group consisting of =O and =S;

Docket No.: C1271.70021US02

each R<sub>7</sub> is independently C<sub>2-7</sub> alkylene;

each R<sub>8</sub> is independently selected from the group consisting of hydrogen, alkyl, alkoxyalkylenyl, and arylalkylenyl;

each  $R_9$  is independently selected from the group consisting of hydrogen and alkyl; each  $R_{10}$  is independently  $C_{3-8}$  alkylene;

each A is independently selected from the group consisting of-O-,-C(O)-, -S(O)<sub>0-2-</sub>,-CH<sub>2-</sub>, and -N(R<sub>4</sub>)-;

each Q is independently selected from the group consisting of a bond,  $-C(R_6)$ -,  $-C(R_6)$ -  $C(R_6)$ -,  $-S(O)_2$ -,  $-C(R_6)$ - $N(R_8)$ -W-,  $-S(O)_2$ - $N(R_8)$ -,  $-C(R_6)$ -O-, and  $-C(R_6)$ - $N(OR_9)$ -;

each V is independently selected from the group consisting of  $-C(R_6)$ -,  $-O-C(R_6)$ -,  $-N(R_8)$ - $C(R_6)$ -, and  $-S(O)_2$ -;

each W is independently selected from the group consisting of a bond, -C(O)-, and -S(O)<sub>2</sub>-; and

a and b are independently integers from 1 to 6 with the proviso that a + b is  $\leq 7$ ; or a pharmaceutically acceptable salt thereof.

- 53. (Previously Presented) The compound or salt of claim 52 wherein R<sub>3</sub> is benzyl.
- 54. (Previously Presented) The compound or salt of claim 52 wherein R<sub>1</sub> is selected from the group consisting of alkyl, arylalkylenyl, aryloxyalkylenyl, hydroxyalkyl, alkylsulfonylalkylenyl, heterocyclylalkylenyl wherein heterocyclyl is optionally substituted by one or more alkyl groups,-X-Y-R<sub>4</sub>, and-X-R<sub>5</sub>; wherein X is alkylene, Y is -N(R<sub>8</sub>)-C(O)-,-N(R<sub>8</sub>)-S(O)<sub>2-</sub>,-N(R<sub>8</sub>)-C(O)-N(R<sub>8</sub>)-, or

; R<sub>4</sub> is alkyl, aryl, arylalkylenyl, or heteroaryl, each of which is optionally substituted by one or more substituents selected from the group consisting of alkyl, alkoxy, halogen, or dialkylamino; and R5 is

## $-N-C(R_8)$ $-N-S(O)_2$ $-N(R_8)-C(O)-N$ A $(CH_2)_a$

55. (Previously Presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 27 in combination with a pharmaceutically acceptable carrier.

26

- 56. (Previously Presented) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of claim 27 to the animal.
- 57. (Previously Presented) A method of treating a viral disease in an animal in need thereof comprising administering a therapeutically effective amount of a compound or salt of claim 27 to the animal.
- 58. (Previously Presented) A method of treating a neoplastic disease in an animal in need thereof comprising administering a therapeutically effective amount of a compound or salt of claim 27 to the animal.
- 59. (Previously Presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 39 in combination with a pharmaceutically acceptable carrier.
- 60. (Previously Presented) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of claim 39 to the animal.
- 61. (Previously Presented) A method of treating a viral disease in an animal in need thereof comprising administering a therapeutically effective amount of a compound or salt of claim 39 to the animal.

62. (Previously Presented) A method of treating a neoplastic disease in an animal in need thereof comprising administering a therapeutically effective amount of a compound or salt of claim 39 to the animal.

27